Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
J Dermatol. 2023 Jul;50(7):912-916. doi: 10.1111/1346-8138.16786. Epub 2023 Mar 20.
Cutaneous angiosarcoma (CAS) is a rare and highly aggressive type of vascular tumor. Although chemoradiotherapy with taxanes is recognized as a first-line therapy for CAS, second-line therapy for CAS remains controversial. From the above findings, the efficacy and safety profiles of taxane-switch (change paclitaxel to docetaxel or vise), eribulin methylate, and pazopanib regimens in second-line chemotherapy were evaluated retrospectively in 50 Japanese taxane-resistant CAS patients. Although there was no significant difference in progression-free survival (P = 0.3528) among the regimens, the incidence of all adverse events (AEs) (P = 0.0386), as well as severe G3 or more AEs (P = 0.0477) was significantly higher in the eribulin methylate group and pazopanib group than in the taxane-switch group. The present data suggest that switching to another taxane should be considered for the treatment of taxane-resistant CAS in second-line therapy based on the safety profiles.
皮肤血管肉瘤（CAS）是一种罕见且高度侵袭性的血管肿瘤。尽管紫杉烷类药物的化疗和放疗被认为是 CAS 的一线治疗方法，但 CAS 的二线治疗仍存在争议。基于上述发现，我们回顾性评估了 50 例日本紫杉烷类耐药性 CAS 患者二线化疗中紫杉醇换用（换用多西紫杉醇或紫杉醇）、艾立布林、帕唑帕尼方案的疗效和安全性。尽管这些方案在无进展生存期（P=0.3528）方面无显著差异，但艾立布林和帕唑帕尼组的所有不良事件（AE）发生率（P=0.0386）以及严重 G3 或更高等级 AE 发生率（P=0.0477）均显著高于紫杉醇换用组。本数据提示，基于安全性考虑，对于紫杉烷类耐药性 CAS 的二线治疗，应考虑换用另一种紫杉烷类药物。
